New One Health framework for AMR published in Nature Portfolio

New research has shown, for the first time, how mixtures of commonly used medications which end up in our waterways and natural environments might increase the development of antibiotic resistant bacteria. 💊 Up to 90 per cent of the medicines we take can pass through the body and into natural environments, via waste water, ending up in the ocean. New research led by the University of Exeter and published in the journal ISME Communications, has revealed that regular drugs used for pain relief, diabetes medication, and hormone replacement can increase the tendency for bacteria to develop the genes needed to resist antibiotic treatments, when combined with a common antibiotic as happens in the environment. 📖 Read more in link in comments 👀 ECEHH European Centre for Environment and Human Health University of Exeter #AMR #AMRResearch

Microbiologist Dr April Hayes from the ECEHH European Centre for Environment and Human Health and the Environment and Sustainability Institute, University of Exeter says “We’ve found that the kind of common medications that many people might routinely take can form a pharmaceutical cocktail in the environment and our waterways, that promotes antibiotic resistance." https://ex.ac.uk/dW9 Graduate School of Environment and Sustainability, University of Exeter

📺 𝐍𝐞𝐰 𝐄𝐧𝐜𝐲𝐜𝐥𝐨𝐩𝐚𝐞𝐝𝐢𝐚 𝐯𝐢𝐝𝐞𝐨 𝐚𝐥𝐞𝐫𝐭! What is 𝐢𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 and why does it matter for antibiotics? It’s a research-based way of studying and overcoming barriers that get in the way of turning health interventions, strategies and policies into effective, high-quality practice. In our latest Encyclopaedia video, GARDP's Fernando Pascual Martinez explains why implementation research matters for antibiotic R&D, and why without it, many promising treatments may never reach those who need them most. 🔗 Watch his short video here: https://lnkd.in/g6srUZb8 #AMR #Antibiotics #REVIVE

💊 Informed decisions. Safer prescriptions. In this Coffee over Genomics discussion, Dr Noopur Kedare (Infectious Disease Specialist, Medicover Hospital) shares how NGS helps guide antibiotic stewardship — ensuring that treatment is precise, and unnecessary antibiotics are avoided when results come back negative. The conversation, moderated by Simran Malik (Medical Science Liaison, HaystackAnalytics), highlights the clinical importance of making evidence-based decisions that protect patients and reduce resistance. ☕ Catch the complete case discussion now on YouTube with the Link Below 👇 https://lnkd.in/dHw-wUZ7 Abhimanyuu Nambisan Pranav Godse siddharth sasane Shuja A. Rohan S SALVI Mohammad Umair Gitesh Srivastava #CoffeeOverGenomics #CIDSCON2025 #AntibioticStewardship #NGS

The #AntibioticCrisis demands new solutions – #Bacteriophages could be the answer, but access in Switzerland is severely limited! 🇨🇭 Viruses that defeat bacteria: Bacteriophages (Phages) are the natural antagonists of pathogenic germs. They show great therapeutic potential, especially for chronic, antibiotic-resistant infections. Worldwide applications document success rates of around 75%, often serving as a last resort. The problem in Switzerland: Despite promising results, patient access is extremely limited. Alexander Harms from ETH Zürich explains that a clear legal framework is missing. Phages are not approved as a medicinal product and can only be used under complex individual compassionate use protocols when all other options have been exhausted. What needs to happen now: Alexander Harms calls for an urgent societal debate and political will to examine viable models – such as the one in Belgium (magistral formulas). We must pave the way for patients in Switzerland to benefit from this potentially life-saving therapy. Read the full interview to learn more about the potential and the regulatory hurdles of phage therapy: https://lnkd.in/eWY4F-4Q

🔎 New #AACjournal issue alert! 📖 Check out the October issue of #AACjournal here: https://lnkd.in/erJvXH5j This issue includes a new review in the series "New Perspectives on Antimicrobial Agents" from Jason M. Pogue et al. It looks at evidence supporting the use of sulbactam-durlobactam for treating carbapenem-resistant Acinetobacter baumannii (CRAB), as well as other potential therapeutic opportunities: https://lnkd.in/etJS3exW

New antibiotics are desperately needed, especially for priority bacterial pathogens. Given that we are struggling to push new antibiotics through the pipeline it is especially important to keep the ones we already have working as long as we can. This can be achieved through a combination of rapid diagnostic tests, good antibiotic stewardship practices, and appropriate education of healthcare professionals as well as laboratory personnel. This coming decade will likely be critical for determining which side of this cliff we come out on.

In Canadian healthcare, over 220,000 patients develop HAIs annually, costing $1 billion and contributing to 12,000 preventable deaths. A major, often overlooked, culprit is biofilms, complex microbial cities thriving in hospital drains. These biofilms are 10 to 1,000 times more resistant to disinfectants and antibiotics. Traditional cleaning methods simply fail to penetrate their protective matrix, allowing rapid regrowth. It is time for a paradigm shift in how we approach environmental cleaning. Discover the science behind true biofilm eradication. Visit removebiofilms.com #InfectionControl #PatientSafety #HealthcareInnovation #Biofilms

Our recent randomized, placebo-controlled clinical study investigated the effect of consuming ADI dose of ciprofloxacin on the human gut microbiome and bacterial susceptibility. We tested whether a daily dose of 372 µg of ciprofloxacin, which is considered safe, could influence antimicrobial resistance (AMR) in Escherichia coli. Key findings: Participants receiving ciprofloxacin showed reduced E. coli susceptibility to the antibiotic. After 27 days, the gut microbiome composition shifted significantly, with a notable decrease in E. coli abundance. Results suggests that even low, regulatory-approved concentrations of antimicrobials in food may impact human health by promoting AMR and change microbial community dynamics, despite limitations such as a small sample size. Article link https://rdcu.be/eKkLK For a quick overview, listen to the ~ 7-minute videobook summary, generated from notebook LM. #AMR #ADI #MSC Chris Kenyon Zina Gestels Saïd Abdellati Thibaut Vanbaelen Irith De Baetselier Els Genbrugge Yven Van Herrewege Dorien Van den Bossche

Next week, (stay tuned!) we will be posting the recordings of the technical briefing we organised with AMR Action Fund and Novo Nordisk Foundation at the European Parliament. The topics covered by our guest experts are quite technical (details of possible PULL mechanisms) and are intended to facilitate the ongoing negotiations for the adoption of the EU pharma package. But we must not forget why all this is being done, why all this is important. It is important because #AMR continues to grow: The recently released WHO GLASS report revealed that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments. It is important because patients have virtually no access to treatments capable of treating the most severe resistances; this is also the case in Europe. It is important because another report recently published by the WHO describes a pipeline of antimicrobials under development that is largely insufficient in view of the health threat. We are not talking about regulations that can improve growth in the eurozone by 0.01%. We are talking about regulations that can kick-start innovation in AMR, which, in the medium term, could save the lives of millions of our fellow citizens. Let us be attentive and precise in our debates, but let us keep this major health issue in the back of our minds.